U.S. Food and Drug Administration has accepted the NDA for Ensartinib Xcovery Holdings, Inc., an oncology focused pharmaceutical company, announced that the FDA has accepted a new Drug Application (NDA) for an ALK inhibitor for the treatment of adult patients with metastatic non-small cell lung cancer.